Capital Impact Advisors, LLC Kodiak Sciences Inc. Transaction History

Capital Impact Advisors, LLC

  • $3.16 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 23, 2023
SELL
$4.81 - $8.88 $6,599 - $12,183
-1,372 Reduced 2.96%
44,926 $278,000
Q3 2022

Nov 21, 2022
BUY
$7.57 - $12.5 $29,401 - $48,550
3,884 Added 9.16%
46,298 $352,000
Q2 2022

Aug 15, 2022
BUY
$5.04 - $9.48 $119,493 - $224,761
23,709 Added 126.75%
42,414 $324,000
Q1 2022

May 16, 2022
BUY
$7.09 - $89.45 $120,210 - $1.52 Million
16,955 Added 968.86%
18,705 $144,000
Q4 2021

Feb 14, 2022
BUY
$80.85 - $128.49 $141,487 - $224,857
1,750 New
1,750 $148,000

Others Institutions Holding KOD

# of Institutions
98
Shares Held
39M
Call Options Held
6.5K
Put Options Held
5.8K
View Full List

About Kodiak Sciences Inc.

KOD Quotes by TradingView
  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $392M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Capital Impact Advisors, LLC Portfolio

Follow Capital Impact Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Impact Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email